GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Other Current Assets

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Other Current Assets : $0.11 Mil (As of Dec. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Other Current Assets?

Eucrates Biomedical Acquisition's other current assets for the quarter that ended in Dec. 2022 was $0.11 Mil.

Eucrates Biomedical Acquisition's quarterly other current assets declined from Jun. 2022 ($0.12 Mil) to Sep. 2022 ($0.04 Mil) but then increased from Sep. 2022 ($0.04 Mil) to Dec. 2022 ($0.11Mil).

Eucrates Biomedical Acquisition's annual other current assets declined from Dec. 2020 ($0.47 Mil) to Dec. 2021 ($0.22 Mil) declined from Dec. 2021 ($0.22 Mil) to Dec. 2022 ($0.11 Mil).


Eucrates Biomedical Acquisition Other Current Assets Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Other Current Assets Chart

Eucrates Biomedical Acquisition Annual Data
Trend Dec20 Dec21 Dec22
Other Current Assets
0.47 0.22 0.11

Eucrates Biomedical Acquisition Quarterly Data
Aug20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.20 0.12 0.04 0.11

Eucrates Biomedical Acquisition Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Eucrates Biomedical Acquisition Other Current Assets Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
250 West 55th Street, Suite 13D, New York, NY, USA, 10019
Website
Eucrates Biomedical Acquisition Corp is a blank check company.
Executives
Stelios Papadopoulos director, 10 percent owner 3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell director 270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro director 2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena director, 10 percent owner, officer: Chief Executive Officer 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal officer: Vice President 250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova officer: Chief Financial Officer 250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe officer: Senior Vice President C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis director, officer: President, COO C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal director C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines